# Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania

> **NCT06813872** · — · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 1 (actual)

## Conditions studied

- Respiratory Syncytial Viruses

## Interventions

- **BIOLOGICAL:** ABRYSVO Vaccination

## Key facts

- **NCT ID:** NCT06813872
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-02-24
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06813872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06813872, "Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06813872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*